According to PWC, "2023 was a reasonably strong year for the pharmaceutical and life sciences sector with both deal value and volume of M&A close to pre-pandemic levels."
Scientists at the UCL Institute of Immunity & Transplantation (IIT) are part of a team to receive £997,000 from the Type 1 Diabetes Grand Challenge, a new partnership involving The Steve Morgan Foundation, Diabetes UK and JDRF.
1. There was no statistically significant difference in recovery time in patients with COVID-19 pneumonia using treatment with abatacept, cenicriviroc, or infliximab compared to standard care. 2. Safety assessment endpoints showed no significant difference between the trial drugs and placebo, as both groups had a similar incidence of serious adverse events (SAE). Evidence Rating Level:
Two anti-inflammatory drugs, abatacept and infliximab, reduced deaths among patients hospitalized with severe COVID-19, according to a national study led by Washington University School of Medicine in St. Louis. William G. Powderly, MD, (right) who led the large clinical trial, discusses patient conditions with Maanasi Samant, MD, in the intensive care unit at Barnes-Jewish Hospital, one of the major trial sites, during the COVID-19 pandemic.